Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure

Chimeric antigen receptor (CAR) T cell therapies have resulted in profound clinical responses in the treatment of CD19-positive hematological malignancies, but a significant proportion of patients do not respond or relapse eventually. As an alternative to CAR T cells, T cells can be engineered to ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Wachsmann, Tassilo L. A., Wouters, Anne K., Remst, Dennis F. G., Hagedoorn, Renate S., Meeuwsen, Miranda H., van Diest, Eline, Leusen, Jeanette, Kuball, Jürgen, Falkenburg, J. H. Frederik, Heemskerk, Mirjam H. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812760/
https://www.ncbi.nlm.nih.gov/pubmed/35127255
http://dx.doi.org/10.1080/2162402X.2022.2033528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812760/
https://www.ncbi.nlm.nih.gov/pubmed/35127255
http://dx.doi.org/10.1080/2162402X.2022.2033528

Ejemplares similares